ID

38140

Beschreibung

Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01926964

Link

https://clinicaltrials.gov/show/NCT01926964

Stichworte

Versionen (1)
  1. 21.09.19 21.09.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

21. September 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT01926964

Englisch

Eligibility Breast Cancer NCT01926964

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients screening criteria
Beschreibung

Screening criteria

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1710032
UMLS CUI [1,2]
C0243161
1. ≥ 18 years old female patients.
Beschreibung

Age | Gender

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0079399
2. resected primary breast cancer (r0 resection).
Beschreibung

Excision Breast Carcinoma

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0728940
UMLS CUI [1,2]
C0678222
3. er-positive breast cancer (defined as at least 10% er-positive malignant cells).
Beschreibung

Oestrogen receptor positive breast cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C2938924
4. her2 negativity by ihc (0 or 1+) or by fish (negative if ratio is ≤ 2.0).
Beschreibung

HER2 Negative Immunohistochemistry | HER2 Negative FISH

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2348908
UMLS CUI [1,2]
C0021044
UMLS CUI [2,1]
C2348908
UMLS CUI [2,2]
C0162789
5. pn0 or pn1a (1-3 positive nodes) by sentinel procedure or axillary dissection.
Beschreibung

TNM Breast tumor staging | Number of Lymph Nodes Positive | Sentinel Lymph Node Biopsy | Excision of axillary lymph nodes

Datentyp

boolean

Alias
UMLS CUI [1]
C0474926
UMLS CUI [2]
C4086646
UMLS CUI [3]
C0796693
UMLS CUI [4]
C0193867
all patients matching the screening criteria should be recorded consecutively in the patient screening and enrollment list.
Beschreibung

Screening criteria Fulfill | Enrollment

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1710032
UMLS CUI [1,2]
C0243161
UMLS CUI [1,3]
C1550543
UMLS CUI [2]
C1516879
patients inclusion criteria for baseline data collection
Beschreibung

Inclusion criteria Baseline Data Collection

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C1442488
UMLS CUI [1,3]
C0010995
1. signed informed consent form for participation to the baseline data collection.
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
in addition, the following information must be available from the pathology report:
Beschreibung

Availability of Information Pathology report

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C1533716
UMLS CUI [1,3]
C0807321
2. estimation of the pathologic maximum tumor diameter (in mm).
Beschreibung

Tumor Diameter Maximum

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C1301886
UMLS CUI [1,3]
C0806909
3. results of er positive tumor cells (in %) and of pgr positive tumor cells (in %) of the invasive component.
Beschreibung

Neoplastic Cell Estrogen receptor positive Percentage | Neoplastic Cell Progesterone receptor positive Percentage | Component Invasive

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0597032
UMLS CUI [1,2]
C0279754
UMLS CUI [1,3]
C0439165
UMLS CUI [2,1]
C0597032
UMLS CUI [2,2]
C0279759
UMLS CUI [2,3]
C0439165
UMLS CUI [3,1]
C1705248
UMLS CUI [3,2]
C0205281
4. proliferation rate by ki-67 staining (mib-1 antibody) in %.
Beschreibung

Proliferation Rate Percentage Ki67 Staining Method | MIB-1 antibody

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514485
UMLS CUI [1,2]
C0871208
UMLS CUI [1,3]
C0439165
UMLS CUI [1,4]
C4055454
UMLS CUI [2]
C1138401
5. result of modified bloom-richardson-elston (bre) grading (grade 1, 2 or 3).
Beschreibung

Modified Bloom-Richardson-Elston grading system

Datentyp

boolean

Alias
UMLS CUI [1]
C1527124
patients eligibility criteria for participation to the study inclusion criteria
Beschreibung

Eligibility Criteria | Participation Clinical Trial Inclusion criteria

Datentyp

boolean

Alias
UMLS CUI [1]
C1516637
UMLS CUI [2,1]
C0679823
UMLS CUI [2,2]
C0008976
UMLS CUI [2,3]
C1512693
1. signed informed consent form for participation to the study sakk 26/10.
Beschreibung

Informed Consent | Participation Clinical Trial Specified

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C0679823
UMLS CUI [2,2]
C0008976
UMLS CUI [2,3]
C0205369
2. the patient is considered suitable to receive adjuvant chemotherapy (ie no medical contraindications to chemotherapy).
Beschreibung

Patients Appropriate Adjuvant Chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1548787
UMLS CUI [1,3]
C0085533
3. invasive breast cancer tissue is available to prepare 39 sections (35 unstained + 4 h&e stained slides, thickness of 5 µm).
Beschreibung

Invasive carcinoma of breast | Availability of Tumor tissue sample | Section Quantity | Unstained Specimen | Hematoxylin and eosin stain method

Datentyp

boolean

Alias
UMLS CUI [1]
C0853879
UMLS CUI [2,1]
C0470187
UMLS CUI [2,2]
C0475358
UMLS CUI [3,1]
C0700320
UMLS CUI [3,2]
C1265611
UMLS CUI [4]
C1883469
UMLS CUI [5]
C0523207
4. performance status: 0 or 1.
Beschreibung

Performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1518965
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. pregnancy
Beschreibung

Pregnancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
2. bilateral invasive breast cancer
Beschreibung

Invasive carcinoma of breast Bilateral

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0853879
UMLS CUI [1,2]
C0238767
3. ct4 and pt4 tumors.
Beschreibung

TNM Breast tumor staging

Datentyp

boolean

Alias
UMLS CUI [1]
C0474926
4. patient with a current psychiatric or medical diagnosis that would interfere with her ability to participate in this study.
Beschreibung

Mental disorder Interferes with Study Subject Participation Status | Disease Interferes with Study Subject Participation Status

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C2348568
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C2348568
5. known metastatic breast cancer (m1).
Beschreibung

Secondary malignant neoplasm of female breast

Datentyp

boolean

Alias
UMLS CUI [1]
C0346993
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Breast Cancer NCT01926964

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Screening criteria
Item
patients screening criteria
boolean
C1710032 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
Age | Gender
Item
1. ≥ 18 years old female patients.
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Excision Breast Carcinoma
Item
2. resected primary breast cancer (r0 resection).
boolean
C0728940 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
Oestrogen receptor positive breast cancer
Item
3. er-positive breast cancer (defined as at least 10% er-positive malignant cells).
boolean
C2938924 (UMLS CUI [1])
HER2 Negative Immunohistochemistry | HER2 Negative FISH
Item
4. her2 negativity by ihc (0 or 1+) or by fish (negative if ratio is ≤ 2.0).
boolean
C2348908 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C2348908 (UMLS CUI [2,1])
C0162789 (UMLS CUI [2,2])
TNM Breast tumor staging | Number of Lymph Nodes Positive | Sentinel Lymph Node Biopsy | Excision of axillary lymph nodes
Item
5. pn0 or pn1a (1-3 positive nodes) by sentinel procedure or axillary dissection.
boolean
C0474926 (UMLS CUI [1])
C4086646 (UMLS CUI [2])
C0796693 (UMLS CUI [3])
C0193867 (UMLS CUI [4])
Screening criteria Fulfill | Enrollment
Item
all patients matching the screening criteria should be recorded consecutively in the patient screening and enrollment list.
boolean
C1710032 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
C1516879 (UMLS CUI [2])
Inclusion criteria Baseline Data Collection
Item
patients inclusion criteria for baseline data collection
boolean
C1512693 (UMLS CUI [1,1])
C1442488 (UMLS CUI [1,2])
C0010995 (UMLS CUI [1,3])
Informed Consent
Item
1. signed informed consent form for participation to the baseline data collection.
boolean
C0021430 (UMLS CUI [1])
Availability of Information Pathology report
Item
in addition, the following information must be available from the pathology report:
boolean
C0470187 (UMLS CUI [1,1])
C1533716 (UMLS CUI [1,2])
C0807321 (UMLS CUI [1,3])
Tumor Diameter Maximum
Item
2. estimation of the pathologic maximum tumor diameter (in mm).
boolean
C0027651 (UMLS CUI [1,1])
C1301886 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
Neoplastic Cell Estrogen receptor positive Percentage | Neoplastic Cell Progesterone receptor positive Percentage | Component Invasive
Item
3. results of er positive tumor cells (in %) and of pgr positive tumor cells (in %) of the invasive component.
boolean
C0597032 (UMLS CUI [1,1])
C0279754 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0597032 (UMLS CUI [2,1])
C0279759 (UMLS CUI [2,2])
C0439165 (UMLS CUI [2,3])
C1705248 (UMLS CUI [3,1])
C0205281 (UMLS CUI [3,2])
Proliferation Rate Percentage Ki67 Staining Method | MIB-1 antibody
Item
4. proliferation rate by ki-67 staining (mib-1 antibody) in %.
boolean
C1514485 (UMLS CUI [1,1])
C0871208 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C4055454 (UMLS CUI [1,4])
C1138401 (UMLS CUI [2])
Modified Bloom-Richardson-Elston grading system
Item
5. result of modified bloom-richardson-elston (bre) grading (grade 1, 2 or 3).
boolean
C1527124 (UMLS CUI [1])
Eligibility Criteria | Participation Clinical Trial Inclusion criteria
Item
patients eligibility criteria for participation to the study inclusion criteria
boolean
C1516637 (UMLS CUI [1])
C0679823 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C1512693 (UMLS CUI [2,3])
Informed Consent | Participation Clinical Trial Specified
Item
1. signed informed consent form for participation to the study sakk 26/10.
boolean
C0021430 (UMLS CUI [1])
C0679823 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C0205369 (UMLS CUI [2,3])
Patients Appropriate Adjuvant Chemotherapy
Item
2. the patient is considered suitable to receive adjuvant chemotherapy (ie no medical contraindications to chemotherapy).
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C0085533 (UMLS CUI [1,3])
Invasive carcinoma of breast | Availability of Tumor tissue sample | Section Quantity | Unstained Specimen | Hematoxylin and eosin stain method
Item
3. invasive breast cancer tissue is available to prepare 39 sections (35 unstained + 4 h&e stained slides, thickness of 5 µm).
boolean
C0853879 (UMLS CUI [1])
C0470187 (UMLS CUI [2,1])
C0475358 (UMLS CUI [2,2])
C0700320 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C1883469 (UMLS CUI [4])
C0523207 (UMLS CUI [5])
Performance status
Item
4. performance status: 0 or 1.
boolean
C1518965 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy
Item
1. pregnancy
boolean
C0032961 (UMLS CUI [1])
Invasive carcinoma of breast Bilateral
Item
2. bilateral invasive breast cancer
boolean
C0853879 (UMLS CUI [1,1])
C0238767 (UMLS CUI [1,2])
TNM Breast tumor staging
Item
3. ct4 and pt4 tumors.
boolean
C0474926 (UMLS CUI [1])
Mental disorder Interferes with Study Subject Participation Status | Disease Interferes with Study Subject Participation Status
Item
4. patient with a current psychiatric or medical diagnosis that would interfere with her ability to participate in this study.
boolean
C0004936 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0012634 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
Secondary malignant neoplasm of female breast
Item
5. known metastatic breast cancer (m1).
boolean
C0346993 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video